[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-detail-345679-en":59,"doc-seo-345679-105":99},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":5,"data":60},{"doc_id":61,"user_id":62,"nickname":63,"user_avatar":64,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":66,"doc_content":67,"file_id":68,"file_url":69,"file_type":70,"file_size":71,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":72,"language":73,"language_code":74,"site_id":75,"html_lang":74,"table_of_contents":76,"faqs":77,"seo_title":78,"seo_description":66,"update_tm":79,"read_time":80,"preview_page_count":19,"preview_urls":81},345679,1099514067438,"River Wang","https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","MicroRNAs as Biomarkers of Cervical Cancers - Review","Invasive cervical cancer causes a substantial share of cancer deaths in women worldwide, largely because early detection remains challenging. Clinical presentations vary and prediction is difficult, so the search for effective biomarkers for earlier diagnosis is critical to lowering mortality. Small microRNAs have emerged as promising biomarker candidates, but microRNA assays still face analytical constraints and limited automation or standardization. This review evaluates the value of microRNAs for early detection, disease monitoring, and treatment effectiveness.","Review  \nMicroRNAs as Biomarkers of Cervical Cancers  \nWojciech Jelski 1,*, Sylwia Okrasinska 2, Jan Mroczko 1, Weronika Rutkowska 2, Klaudia Zieziula 2 and Barbara Mroczko 1,3  \nAcademic Editor: Marco Ciotti  \nReceived: 4 May 2026  \nRevised: 10 June 2026  \nAccepted: 10 June 2026  \nPublished: 12 June 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Department of Biochemical Diagnostics, Medical University, 15-269 Bialystok, Poland  \n2 Department of Biochemical Diagnostics, University Hospital, 15-269 Bialystok, Poland  \n3 Department of Neurodegeneration Diagnostics, Medical University, 15-269 Bialystok, Poland  \n* [Correspondence: wojciech.jelski@umb.edu.pl](Correspondence: wojciech.jelski@umb.edu.pl); Tel.: +48-85-746-8587; Fax: +48-85-746-8585  \nAbstract  \nInvasive cervical cancer is a very common cause of cancer death in women worldwide, primarily due to late detection of this cancer. The clinical manifestations of cervical cancer vary significantly and are difficult to predict. Finding new effective biomarkers for the early detection of cervical cancer is essential to reducing mortality. Small microRNA molecules have also recently emerged as potential biomarker candidates in the diagnosis of cervical cancer. Despite analytical limitations in microRNA assays and the lack of automated and standardized tests, validated and prospective systematic evaluation of this new parameter in cervical cancer deserves further development. This review describes the importance and potential usefulness of microRNAs in detecting cervical cancer at an early stage, monitoring the course of the disease, and assessing the effectiveness of treatment. The diagnostic importance of microRNAs is well documented in many publications, suggesting that, as microRNA research progresses, they may become a useful diagnostic tool for cervical cancer.  \nKeywords: microRNA; cervical cancer; biomarker  \n1. Introduction  \nCervical cancer (CC) is the fourth most common malignancy (after breast, colon, and lung cancer) and the fourth leading cause of cancer deaths in women worldwide. In 2022, an estimated 660,000 new cases of cervical cancer and approximately 350,000 deaths were reported worldwide [1]. Among women of reproductive age, CC ranked among the top third most common cancers and causes of cancer deaths in over 150 countries. If 2022 rates do not decrease, the global burden of CC is estimated to increase to over 760,000 new cases (about 18%) by 2030. Significant geographic variations in cervical cancer incidence are observed across regions of the world. Highly developed countries have incidence rates half as low and mortality rates five times lower than those in low-developed countries. Thus, cervical cancer remains a significant challenge for 21st-century medicine worldwide, especially since it is largely preventable through effective therapeutic approaches [2]. Most CC cases (about 99%) are associated with the oncogenic human papillomavirus (HPV). The most common HPV type in cervical cancer is HPV-16, followed by HPV-18, HPV-45, and HPV-31 [3] . The process of carcinogenesis from normal epithelium to invasive cervical cancer can take more thana decade. In early stages I and II, the total survival rate for women with CC is 72–91%; however, in stage IVa, this rate drops sharply to about 16% . This high mortality rate from cervical cancer is due to its asymptomatic and nonspecific nature in the early stages, which significantly complicates early detection [4] . Detecting early stages of the disease with a  \ngood prognosis is not easy. Currently, there is no standardized, reliable screening test due to the complex molecular biology of oncogenesis in cervical cancer. Understanding the biomolecular pathomechanisms of CC development could lead to the development of more reliable and sensitive screen","cbCaibz9hwz3bdJN","https://ap.wps.com/l/cbCaibz9hwz3bdJN","pdf",727260,14,"English","en",105,"# Introduction\n## Burden of cervical cancer and need for better screening\n## Biomarkers and role of microRNAs\n# Identification and screening process\n## Search strategy and inclusion approach\n## Article selection flow (Figure 1)","[{\"question\":\"Why are new biomarkers important for cervical cancer?\",\"answer\":\"Cervical cancer mortality is strongly influenced by late detection, and screening lacks a standardized, reliable test. New biomarkers could improve early identification and risk prediction.\"},{\"question\":\"What role do microRNAs play in cervical cancer?\",\"answer\":\"MicroRNAs are involved in cervical cancer pathomechanisms through abnormal gene expression. Their profiles may support diagnosis, prognosis, and response to treatment.\"},{\"question\":\"What limitations currently affect microRNA-based testing?\",\"answer\":\"MicroRNA assays face analytical limitations, and there is a lack of automated and standardized tests. The review highlights the need for validated, prospective evaluation.\"}]","MicroRNAs as Biomarkers of Cervical Cancers - Review | PDF",1790058569,35,[82,86,90,95],{"page_no":8,"url":83,"width":84,"height":85},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6f11004a08fa8e2270e2b5e27656a18e.webp",983,1390,{"page_no":14,"url":87,"width":88,"height":89},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a557d13120a10c9bb67a04345fbac4be.webp",982,1388,{"page_no":91,"url":92,"width":93,"height":94},3,"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a47c5b9acf5821d926712b54b189174e.webp",981,1387,{"page_no":19,"url":96,"width":97,"height":98},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f6213c17757a041398495dbfb1fc4c47.webp",980,1385,{"code":4,"msg":100,"data":101},"ok",{"site_id":75,"language":74,"slug":102,"title":65,"keywords":103,"description":66,"schema_data":104,"social_meta":157,"head_meta":159,"extra_data":161,"updated_unix":162},"micrornas-as-biomarkers-of-cervical-cancers-review","",{"@graph":105,"@context":156},[106,119,139],{"@type":107,"itemListElement":108},"BreadcrumbList",[109,113,115,117],{"item":110,"name":111,"@type":112,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":114,"name":9,"@type":112,"position":14},"https://docshare.wps.com/document/",{"item":116,"name":40,"@type":112,"position":91},"https://docshare.wps.com/document/research-report/",{"item":118,"name":65,"@type":112,"position":19},"https://docshare.wps.com/document/micrornas-as-biomarkers-of-cervical-cancers-review/345679/",{"url":118,"name":65,"@type":120,"image":121,"author":126,"headline":65,"publisher":128,"fileFormat":131,"inLanguage":74,"description":66,"dateModified":132,"datePublished":133,"encodingFormat":131,"isAccessibleForFree":134,"interactionStatistic":135},"DigitalDocument",{"url":122,"@type":123,"width":124,"height":125},"https://docshare.wps.com/thumbnails/micrornas-as-biomarkers-of-cervical-cancers-review/345679.png","ImageObject",300,407,{"name":63,"@type":127},"Person",{"url":110,"name":129,"@type":130},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":136,"interactionType":137,"userInteractionCount":44},"InteractionCounter",{"@type":138},"ViewAction",{"@type":140,"mainEntity":141},"FAQPage",[142,148,152],{"name":143,"@type":144,"acceptedAnswer":145},"Why are new biomarkers important for cervical cancer?","Question",{"text":146,"@type":147},"Cervical cancer mortality is strongly influenced by late detection, and screening lacks a standardized, reliable test. New biomarkers could improve early identification and risk prediction.","Answer",{"name":149,"@type":144,"acceptedAnswer":150},"What role do microRNAs play in cervical cancer?",{"text":151,"@type":147},"MicroRNAs are involved in cervical cancer pathomechanisms through abnormal gene expression. Their profiles may support diagnosis, prognosis, and response to treatment.",{"name":153,"@type":144,"acceptedAnswer":154},"What limitations currently affect microRNA-based testing?",{"text":155,"@type":147},"MicroRNA assays face analytical limitations, and there is a lack of automated and standardized tests. The review highlights the need for validated, prospective evaluation.","https://schema.org",{"og:url":118,"og:type":158,"og:title":65,"og:site_name":129,"og:description":66},"article",{"robots":160,"canonical":118},"index,follow",{"doc_id":61,"site_id":75},1790196709]